Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 6, 2025
Daily News
August 6, 2025
- Nippon Zoki Snags Japan Rights to Kagoshima University Offshoot’s Oncolytic Virus
August 6, 2025
- Japan Publishes List of 203 Suspected or Confirmed Nitrosamine Impurities in Medicines
August 6, 2025
- Eisai Sees Subcutaneous Autoinjector as Key to Boosting US Demand for Leqembi
August 6, 2025
- MHLW Panel OKs RX-to-OTC Switch of Medicon Cough Suppressant for Children
August 6, 2025
- Takeda Taps AI Demand Forecasting for 70% of Products, Aims to Bolster Supply Reliability
August 6, 2025
- Sumitomo Files iPS Cell-Derived Dopaminergic Progenitor Cells in Japan
August 6, 2025
- Japan Approves Updated Spikevax for LP.8.1 Omicron Strain
August 6, 2025
- MHLW Device Review Chief Pledges Evidence-Based Approvals amid Diversifying Technologies
August 6, 2025
- FRONTEO Showcases Pharma Use Cases for AI Engine in Target Discovery and Future Toxicity Assessment
August 6, 2025
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…